21. P136 Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort. (25th January 2019) Authors: Peyrin-Biroulet, L; Feagan, B; Pai, R K; Arulmani, U; Boruvka, A; Oh, Y S; Scherl, A; Scalori, A; Arrisi, P; Tole, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. P185 A comparison of early response parameters to inform a treat-to-target approach in ulcerative colitis. (15th January 2020) Authors: Dulai, P; Feagan, B; Sands, B; Lasch, K; Lirio, R; Feng, D Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. P186 Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: A post-hoc analysis of the UNITI trials. (16th January 2018) Authors: Ghosh, S; Sattin, B; Tornatore, V; Gasink, C; Gao, L -L; Sloan, S; Rutgeerts, P; Sands, B; Hanauer, S; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn's disease studies. (16th January 2018) Authors: Colombel, J -F; Gasink, C; Oortwijn, A; van Kruchten, R; Sloan, S; Laliman, V; Rutgeerts, P; Ghosh, S; Sandborn, W; Feagan, B; Sands, B Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. P311 Reliability of computed tomography enterography for evaluation of stricturing Crohn's disease: Development of a Crohn's disease stricture index. (30th January 2023) Authors: Rieder, F; Ma, C; Hanzel, J; Fletcher, J G; Baker, M; Wang, Z; Guizetti, L; Patel, M; Niu, J; Shackelton, L; Ottichilo, R; Santillan, C; Capozzi, N; Taylor, S A; Zhou, G; Bruining, D; Feagan, B; Jairath, V; Rimola, J Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. P343 Efficacy of ustekinumab in Crohn's disease at maintenance Week 56: IM-UNITI study. (25th January 2019) Authors: Sandborn, W J; Sands, B; Colombel, J-F; Gasink, C; Patel, R; Jacobstein, D; Gao, L-L; Ghosh, S; Targan, S; De Villiers, W; Hanauer, S B; Rutgeerts, P; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study. (27th May 2021) Authors: Peyrin-Biroulet, L; Loftus Jr, E V; Hibi, T; Birchwood, C; Yun, C; Zhao, S; Liu, X; Rogler, G; Danese, S; Colombel, J F; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. P391 Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trials. (30th January 2023) Authors: Sands, B E; Feagan, B; Gibble, T H; Keohane, A; Eastman, W; Traxler, K; Schreiber, S; Jairath, V; Armuzzi, A Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i523 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn's disease. (27th May 2021) Authors: Pai, R; De Hertogh, G; Reinisch, W; Harpaz, N; Feagan, B; Agada, N; Pollack, P; Chan, L S; Protic, M; Magro, F Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trials. (30th January 2023) Authors: Ghosh, S; Feagan, B; Parra, R S; Lopes, S; Steinlauf, A; Kakuta, Y; Joshi, N; Lee, W J; Remple, V; Lacerda, A P; Zhou, Q; Xuan, S; Louis, E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i560 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗